Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 / 抑制剂/激动剂 / 内分泌学/激素 / ACE / Quinapril HCl

盐酸喹那普利 /Quinapril HCl {[allProObj[0].p_purity_real_show]}

货号：A797055 同义名： CI-906;Quinapril (hydrochloride)

Quinapril HCl是一种血管紧张素转换酶（ACE）抑制剂的前药，Ki值为20 μM，广泛用于治疗高血压和充血性心力衰竭。

Quinapril HCl 化学结构 CAS号：82586-55-8
Quinapril HCl 化学结构
CAS号：82586-55-8
Quinapril HCl 3D分子结构
CAS号：82586-55-8
Quinapril HCl 化学结构 CAS号：82586-55-8
Quinapril HCl 3D分子结构 CAS号：82586-55-8
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} 		{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Quinapril HCl 纯度/质量文件 产品仅供科研

货号：A797055 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Neuron, 2025. Ambeed. [ A1440350 ]
• Nature Communications, 2025, 16, 996. Ambeed. [ A111960 , A505336 ]
• JACS, 2025. Ambeed. [ A349578 , A2270125 ]
• PLoS Biol., 2025, 23(2): e3002961. Ambeed. [ A181909 ]
• Redox Rep., 2025, 30(1): 2454887. Ambeed. [ A1155014 ]
更多 >

Quinapril HCl 生物活性

靶点

  • ACE
描述 Quinapril Hydrochloride is the hydrochloride salt form of quinapril, a prodrug and non-sulfhydryl angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Quinapril inhibits the contractile and pressor effects of angiotensin I in rabbit aorta and in rats, respectively, and lowers blood pressure in both high- and normal-renin rodent and diuretic-treated dog models of hypertension. Long-term toxicology studies show that quinapril is not teratogenic, carcinogenic, or mutagenic[3]. Quinapril produced minimal adverse effects on renal function in both patients with normal renal function and in those with pre-existing renal impairment[4]. Quinaprilat has a strong binding capacity to tissue ACE allowing for once-daily dosing. The recommended starting dose for quinapril is 20 mg/d. Quinapril's antihypertensive efficacy is equal to that of captopril and enalapril[5]. Hemodynamic studies in dogs indicate that quinapril decreases total peripheral and renal vascular resistance. Quinapril is well tolerated in a variety of pharmacologic safety screens and its toxicity profile is similar to that of other ACE inhibitors[6].

Quinapril HCl 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02817360 Heart Diseases ... 展开 >> Diabetes Mellitus, Type 2 收起 << Phase 4 Recruiting February 2021 Austria ... 展开 >> Internistische Ordination Recruiting Mödling, Niederösterreich, Austria, 2340 Contact: Christian Feinböck, MD    +43 2236 869 142    office@dr-feinboeck.at    Contact: Christiane Feinböck    +43 2236 869 142    office@dr-feinboeck.at    Sub-Investigator: Egbert Seyfried, MD          Principal Investigator: Christian Feinböck, MD          Klinischen Abteilung für Endokrinologie und Diabetologie MU Graz Recruiting Graz, Steiermark, Austria, 8036 Contact: Harald Sourij    +43-316-385-80363    ha.sourij@medunigraz.at    Contact: Michael Zink    +43-680-128-5120    m.zink@medunigraz.at    Sub-Investigator: Julia Mader, MD Prof          Sub-Investigator: Eva Novak, MD          Sub-Investigator: Caren Sourij, MD          Konventhospital der Barmherzigen Brüder Abteilung für Innere Medizin Recruiting Linz, Upper Austria, Austria, 4021 Contact: Martin Clodi, Prof.Dr.       martin.clodi@bblinz.at    Principal Investigator: Martin Clodi, Prof.Dr.          Sub-Investigator: Michael Resl, Dr.          Krankenanstalt Rudolfstiftung, 1. Medizinische Abteilung Recruiting Vienna, Austria, 1030 Contact: Bernhard Ludvik, Prof.Dr.    +43 1 711 65 ext 2107    bernhard.ludvik@wienkav.at    Principal Investigator: Bernhard Ludvik, Prof.Dr.          Sub-Investigator: Eva-Christina Krzizek, Dr.          Sub-Investigator: Johanna Brix, Dr.          Sub-Investigator: Astrid Feder, Dr.          Sub-Investigator: Florian Hoellerl, Dr.          Medical University of Vienna Univ.Clinic for Internal Medicine II Department of Cardiology Recruiting Vienna, Austria, 1090 Contact: Martin Huelsmann, Doz.Dr.    +43 1 40400 ext 46140    martin.huelsmann@meduniwien.ac.at    Principal Investigator: Martin Huelsmann, Doz.Dr.          Sub-Investigator: Raphael Wurm, Dr.          Univ. Klinik für Innere Medizin III Med. Uni Wien Recruiting Vienna, Austria, 1090 Contact: Anton Luger, Prof.Dr.    00 43 1 40400 ext 43100    anton.luger@meduniwien.ac.at    Principal Investigator: Anton Luger, Prof.Dr.          Sub-Investigator: Michael Krebs, Prof.Dr.          Universitätsklinik für Augenheilkunde und Optometrie Medizinische Universität Wien Recruiting Vienna, Austria, 1090 Contact: Sonja Prager, Dr.    +43 1 40400 ext 79470    sonja.prager@meduniwien.ac.at    Principal Investigator: Sonja Prager, Dr.          Sub-Investigator: Julia Hafner, Dr.          Diabetes & Stoffwechselambulanz Gesundheitszentrum Wien Süd Recruiting Vienna, Austria, 1100 Contact: Helmut Brath, OA Dr.    +43 1 60122 ext 4264    helmut.brath@wgkk.at    Principal Investigator: Helmut Brath, OA Dr.          3. Med. Abtlg., KH Hietzing mit Neurologischem Zentrum Rosenhügel Recruiting Vienna, Austria, 1130 Contact: Rudolf Prager, Prof.Dr.    +43 1 80110 ext 2351    rudolf.prager@wienkav.at    Principal Investigator: Rudolf Prager, Prof.Dr.          Sub-Investigator: Slobodan Peric, Dr.          Zentrum für Klinische Studien Recruiting Wien, Austria, 1060 Contact: Ursula Hanusch, MD    +43 1 266 21 91    dr.hanusch@dieinternistin.com    Contact: Michaela Mauritz    +43 1 266 21 91    office@dieinternistin.com    Sub-Investigator: Marita Spak, MD          Netherlands Maastricht University Medical Center; Dep. Cardiology Recruiting Maastricht, Netherlands, 6202 Contact: Hans-Peter Brunner-La Rocca, MD Prof    +31 43-3877097    hp.brunnerlarocca@mumc.nl    Contact: Mireille Spanjers    +31 43-3877099    m.spanjers@mumc.nl    Sub-Investigator: Nick Marks, MD          Sub-Investigator: Wouter Robaeys, MD          New Zealand Christchurch Heart Institute Recruiting Christchurch, New Zealand, 8140 Contact: Richard Troughton, MD Prof    +64 3 364 1063    Richard.Troughton@cdhb.health.nz    Contact: Lorraine Skelton    +64 3 364 1063    lorraine.skelton@cdhb@health.nz    Principal Investigator: Richard Troughton, MD Prof 收起 <<
NCT00295542 Hypertension Phase 4 Completed - Spain ... 展开 >> Hospital Clinico Universitario Santiago de Compostela, Spain, 15706 收起 <<
NCT00741585 Essential Hypertension ... 展开 >> Cardiovascular Disease Stroke Chronic Kidney Disease 收起 << Phase 4 Completed - Spain ... 展开 >> CS Friol Friol, Lugo, Spain, 27220 CS Baiona Baiona, Pontevedra, Spain, 36300 CS Bueu Bueu, Pontevedra, Spain, 36930 CS A Estrada La Estrada, Pontevedra, Spain, 26680 CS A Guarda La Guardia, Pontevedra, Spain, 36780 CS Valmiñor Nigran, Pontevedra, Spain, 36250 CS Panxón Nigrán, Pontevedra, Spain, 36340 CS Tomiño Tomiño, Pontevedra, Spain, 36200 Bioengineering & Chronobilogy Labs., University of Vigo Vigo, Pontevedra, Spain, 36200 Hospital do Meixoeiro Vigo, Pontevedra, Spain, 36200 CS Calle Cuba Vigo, Pontevedra, Spain, 36202 CS A Doblada Vigo, Pontevedra, Spain, 36205 CS Coia Vigo, Pontevedra, Spain, 36209 CS Sardoma Vigo, Pontevedra, Spain, 36214 CS Teis Vigo, Pontevedra, Spain, 36216 CS Vilaboa Vilaboa, Pontevedra, Spain, 36141 CS San Roque Vilagarcía De Arousa, Pontevedra, Spain, 36600 CS Fingoi Lugo, Spain, 27002 Complexo Hospitalario Universitario de Ourense Orense, Spain, 32005 CS Lerez Pontevedra, Spain, 36156 收起 <<

Quinapril HCl 参考文献

[1]Song JC, White CM. Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24.

[2]Culy CR, Jarvis B. Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders. Drugs. 2002;62(2):339-85.

[3]Kaplan HR, Taylor DG, Olson SC. Quinapril: overview of preclinical data. Clin Cardiol. 1990 Jun;13(6 Suppl 7):VII6-12

[4]Canter D, Frank GJ, Knapp LE, McLain RW. The safety profile of quinapril: is there a difference among ACE inhibitors? Clin Cardiol. 1990 Jun;13(6 Suppl 7):VII39-42

[5]Cetnarowski-Cropp AB. Quinapril: a new second-generation ACE inhibitor. DICP. 1991 May;25(5):499-504

[6]Kaplan HR, Taylor DG, Olson SC, Andrews LK. Quinapril--a preclinical review of the pharmacology, pharmacokinetics, and toxicology. Angiology. 1989 Apr;40(4 Pt 2):335-50

Quinapril HCl 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.11mL

0.42mL

0.21mL

10.53mL

2.11mL

1.05mL

21.05mL

4.21mL

2.11mL

Quinapril HCl 技术信息

CAS号82586-55-8
分子式C25H31ClN2O5
分子量 474.977
别名 CI-906;Quinapril (hydrochloride);PD-109452-2;Quinapril hydrochloride
运输蓝冰
存储条件

In solvent -20°C:3-6个月-80°C:12个月

Pure form Inert atmosphere,2-8°C
溶解方案

DMSO: 105 mg/mL(221.06 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 50 mg/mL(105.27 mM)

请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用； 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶
方案一
方案二
配制的工作液建议现用现配，短期内尽快用完。 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。
方案一
动物实验配方

Tags: Quinapril | 82586-55-8 | CI-906 | CI906 | CI 906 | ACE Inhibitor | Metabolic Enzyme/Protease | Angiotensin-converting Enzyme (ACE) | 仅供科研使用 | AmBeed-信号通路专用抑制剂 | Quinapril HCl 纯度/质量文件 | Quinapril HCl 生物活性 | Quinapril HCl 临床数据 | Quinapril HCl 参考文献 | Quinapril HCl 实验方案 | Quinapril HCl 技术信息

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 Ambeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z